BCL2 and acute myeloid leukemia: A genome-wide loss-of-function CRISPR/Cas9 screen performed in the MOLM-13 AML cell line identified that mitochondrial organization proteins act as synthetic lethal targets when combined with the new AML medication, the BH3 mimetic and potent BCL-2 antagonist - Venetoclax.